A Study of Cardiovascular Events iN Diabetes Plus
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
ASCEND PLUS is testing whether, for people with type 2 diabetes who have not previously had a heart attack or stroke, regularly taking a tablet called semaglutide can safely help to reduce heart attacks, strokes, mini-strokes, the need for any procedures to unblock or bypass an artery to their heart, and the chance of dying because of vascular problems.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Healthy Volunteers: f
View:
• Adults aged at least 55 years at the time of the Screening assessment
• Type 2 Diabetes Mellitus (based on self-reported medical history)
Locations
Other Locations
United Kingdom
Clinical Trial Service Unit and Epidemiological Studies Unit
RECRUITING
Oxford
Contact Information
Primary
Ryonfa Lee
ascend-plus@ndph.ox.ac.uk
01865 743743
Time Frame
Start Date: 2023-03-13
Estimated Completion Date: 2048-08-17
Participants
Target number of participants: 20000
Treatments
Active_comparator: Oral semaglutide
14mg daily (option to reduce to 7mg daily)
Placebo_comparator: Placebo
Related Therapeutic Areas
Sponsors
Leads: University of Oxford
Collaborators: Novo Nordisk A/S